Life settlement underwriting is the process by which independent specialist firms estimate the life expectancy of an insured, anchoring every other calculation in the investment thesis. The four major U.S. underwriters — 21st Services, ISC Services, Fasano Associates, and Predictive Resources — operate under Actuarial Standards Board ASOP No. 48, using a debit/credit system that translates medical conditions into mortality multipliers applied against base population mortality tables. Investors should read the LE report for medical evidence quality, the A/E (actual-to-expected) ratio history of the underwriter, the methodology disclosure, and confidence intervals around the central LE estimate. Invest in life settlements through HYV with policies that include independent LE underwriting documentation on every opportunity.
Most articles about life settlement underwriting describe what the underwriter does. That's useful but incomplete for an accredited investor evaluating a specific policy. The harder and more important skill is reading and interpreting an LE report someone else produced — recognizing strong methodology, spotting red flags, and calibrating your investment thesis against the realistic range of the underwriter's estimate. After more than two decades evaluating LE reports across thousands of policies, here is the framework that separates investors who genuinely understand underwriting from those who treat the LE number as a black box.
Why life expectancy underwriting matters more than any other variable
Every other calculation in a life settlement investment depends on the LE estimate. The purchase price reflects it. The projected IRR derives from it. The premium reserve sizing uses it. The holding period assumption is built on it. If the LE is wrong by 12-24 months, your IRR projection moves materially — sometimes 200-400 basis points in either direction. No other diligence input has the same downstream impact across the investment thesis.
This is why the institutional standard is independent third-party LE underwriting from recognized firms — and why "in-house" LE estimates from platforms or brokers are a structural red flag. The conflict of interest is direct: a platform that produces its own LE estimate has economic incentive to optimize for transaction volume over estimate accuracy. Independent underwriters have no economic interest in any specific transaction; their reputation depends on long-term A/E ratio accuracy across thousands of cases. The institutional firms that drive the secondary market — Apollo Global Management, Berkshire Hathaway, Partner Re, major family offices — require independent LE underwriting on every acquisition for this exact reason.
Beyond the structural argument, the practical implication for accredited investors is that the LE report is the single most important document in the pre-investment package. More important than the premium schedule. More important than the carrier rating. The LE estimate determines whether the projected return makes sense — and whether the purchase price reflects realistic mortality timing.
Typical net IRR impact of a ±12-24 month error in life expectancy estimate at acquisition. A policy projected at 11% IRR with a 60-month LE can land at 8% if the insured lives to 84 months, or 14% if they pass at 36 months. This is why LE underwriting quality is the single most consequential diligence variable. See the SEC Investor Bulletin on Life Settlements for the regulator's framing.
How the underwriting process actually works
The mechanics of life expectancy underwriting are more structured than most investors realize. The major firms operate under a defined methodology framework — the Actuarial Standards Board's ASOP No. 48 (Actuarial Standard of Practice 48) — that sets professional standards for life settlement mortality analysis. Within that framework, the working method is a debit/credit system applied against base population mortality tables.
Step 1 — Base mortality table assignment
Every LE underwriting starts with a base population mortality table — typically the Society of Actuaries 2015 Valuation Basic Table (VBT) or a proprietary base table calibrated to insured-population data. The base table provides expected mortality rates by age and gender for a healthy population without specific impairments. This is the starting point: a 78-year-old male non-smoker has a baseline mortality probability that comes from the table.
Step 2 — Medical evidence collection
The underwriter collects comprehensive medical evidence: HIPAA-compliant medical records covering 2-5 years of history, attending physician statements, hospitalization summaries, prescription drug records, and lab results. The quality and completeness of this evidence directly affects estimate accuracy. A complete evidence package allows precise impairment scoring; a thin or incomplete package introduces uncertainty.
Step 3 — Debit/credit application
This is the operational core of the methodology. The underwriter reviews medical conditions and applies "debits" (which increase mortality risk above baseline) or "credits" (which decrease mortality risk below baseline) to produce a final mortality multiplier. Diabetes might add 50-100 debits; controlled hypertension might add 25 debits; coronary artery disease with stents might add 100-200 debits depending on severity. Active treatment compliance, lifestyle factors, and recent biomarker improvements can add credits that offset some debits. The final multiplier is expressed as a percentage of standard mortality — a "150% multiplier" means the insured has 1.5× the mortality risk of a standard healthy individual the same age and gender.
Step 4 — Life expectancy calculation
Applying the mortality multiplier to the base table produces a modified mortality curve specific to the insured. Integrating that curve produces the central life expectancy estimate — typically expressed in months. A 78-year-old male non-smoker with a 150% multiplier might have a central LE of 84 months, compared to 108 months for an unimpaired peer. The report includes the central estimate plus distributional information — typically the median LE plus the 25th and 75th percentile points to indicate the uncertainty range.
Step 5 — Quality control and peer review
Major underwriting firms apply internal peer review to every report — a second underwriter examines the impairment scoring, methodology application, and final calculation before the report is finalized. This catches scoring errors and ensures consistency across the firm's output. The peer review process is part of why institutional buyers require named-firm underwriting rather than freelance estimates.
The anatomy of an LE report — section by section
An institutional LE report runs 8-15 pages and contains eight standard sections. Reading them properly requires knowing what each section reveals about both the insured and the underwriter's methodology. Here is the section-by-section walkthrough investors should apply to every LE report in their pre-investment review.
Insured demographic profile
Age, gender, smoking status, base mortality table reference. Cross-check this matches the policy contract data.
Medical records summary
List of records reviewed (APS, lab work, hospital summaries) with date ranges. Look for 2-5 years of evidence depth.
Impairment scoring detail
Each medical condition listed with debit/credit assignment and rationale. Transparent scoring is a quality marker.
Mortality multiplier
Final percentage applied against base mortality table. Should reconcile with summed debits/credits in section 3.
Central LE estimate
Median life expectancy in months with confidence intervals (25th/75th percentile typically). Wide intervals flag uncertainty.
Methodology disclosure
Explanation of base table, multiplier source, ASOP 48 compliance. Transparency on methodology is non-negotiable.
Underwriter credentials
Named medical underwriter and reviewing underwriter. Look for board-certified physicians and credentialed actuaries.
Firm A/E ratio track record
Disclosure of the underwriter's actual-to-expected ratio across historical case portfolio. The single best quality metric.
Two sections deserve particular investor attention. Section 5 (central LE with confidence intervals) is where most investors stop reading. The point estimate is what gets used in IRR projection, but the width of the confidence interval is equally informative. A 60-month LE with a 48-72 month interval is much more reliable than a 60-month LE with a 36-96 month interval — even though both have the same point estimate. The interval width tells you how much the underwriter's estimate could be wrong.
Section 8 (A/E ratio track record) is the single most important indicator of underwriter quality. The A/E ratio compares actual mortality observed in the underwriter's case portfolio to the expected mortality the underwriter projected. An A/E ratio of 100% means the underwriter is calibrated correctly across their book — actuals match expectations. Above 100% means actuals are coming in heavier (insureds dying sooner than projected, IRR outperforming projections). Below 100% means actuals are coming in lighter (insureds living longer, IRR compressing). Sustained A/E below 90% across a meaningful sample size is a structural quality concern; sustained 95-105% is the institutional benchmark.
Browse vetted life settlement opportunities
Every HYV opportunity includes the full LE report from a recognized independent underwriter — 21st Services, ISC, Fasano, or Predictive Resources — along with the supporting medical evidence, methodology disclosure, and A/E track record.
Browse ListingsThe four major underwriting firms compared
Roughly 90% of institutional LE underwriting in the U.S. life settlement market flows through four firms: 21st Services, ISC Services, Fasano Associates, and Predictive Resources. Each has a distinct methodology, founding history, and operational specialty. Knowing the differences helps investors interpret reports across multiple sources.
Four institutional firms head-to-head
For accredited investors, the practical implication is that institutional opportunities should include LE reports from at least one of these four firms — and ideally two for high-value policies. Reports from less-recognized firms or in-house platform underwriting represent a different quality tier and warrant additional skepticism. Many top-tier opportunities include dual reports from two of the four firms, providing cross-validation that single-source underwriting can't match. The accredited investors who invest in life settlements through HYV see this multi-source standard applied across the platform's institutional inventory.
Reading dual-report cases
When a policy comes with two independent LE reports, the diligence question becomes how to reconcile them. Two reports rarely produce identical numbers. A 60-month estimate from 21st Services alongside a 66-month estimate from Fasano is the typical pattern — meaningful agreement with modest divergence. Wider divergence (60-month vs 84-month) warrants explicit reconciliation: which firm has stronger A/E history with this specific impairment profile? Which methodology is better calibrated for the insured's age band? Reconciliation discipline is a marker of sophisticated diligence. The detailed walkthrough of how reports integrate into a complete diligence stack is covered in our step-by-step investment guide.
- Independent LE underwriting from a recognized firm is non-negotiable. 21st Services, ISC, Fasano, or Predictive Resources are the institutional standard. In-house or unrecognized estimates introduce systematic bias risk.
- Read all eight sections — particularly Section 5 (intervals) and Section 8 (A/E history). The point estimate isn't the full picture; the uncertainty range and the firm's historical accuracy are equally informative.
- Look for ASOP No. 48 compliance disclosure. Methodology that doesn't reference the Actuarial Standards Board framework is operating below institutional norm.
- Prefer dual-report cases when face value justifies the cost. Policies above $1M-$2M typically warrant two independent LE reports for cross-validation.
Invest in life settlements with full underwriting transparency
HYV opportunities include independent LE reports from recognized firms with full methodology disclosure, A/E track record, and supporting medical evidence — same standards used by Apollo, Berkshire Hathaway, and Partner Re for their direct ownership acquisitions.
U.S. life expectancy underwriting for life settlements operates under the Actuarial Standards Board's ASOP No. 48 (Actuarial Standard of Practice 48), which sets professional standards for life settlement mortality analysis including methodology disclosure, peer review requirements, and compliance documentation. The four major U.S. underwriting firms — 21st Services (founded 1997), ISC Services (founded 2003), Fasano Associates (founded 1999), and Predictive Resources (founded 2010) — collectively cover approximately 90% of institutional LE underwriting in the U.S. secondary market. State-level oversight of life settlement transactions operates through the framework maintained by the National Association of Insurance Commissioners (NAIC) Viatical Settlements Model Act and NCOIL Life Settlement Model Act, adopted across 43 U.S. states plus DC.
The debit/credit system applied within ASOP 48 methodology translates medical impairments into mortality multipliers expressed as percentages of standard population mortality. Common impairment scoring ranges include diabetes (50-100 debits), controlled hypertension (25-50 debits), coronary artery disease with stents (100-200 debits), and active malignancy with treatment (200-400+ debits). Final multipliers between 100% and 250% are typical for the senior life settlement underwriting population. Mortality multipliers are applied against base population mortality tables — typically the Society of Actuaries 2015 Valuation Basic Table or proprietary firm-specific impaired-life tables. Federal investor accreditation rules under SEC Rule 501 of Regulation D apply to all life settlement investment recommendations; the SEC Investor Bulletin on Life Settlements and FINRA investor bulletin on life settlements describe the regulator's framing.
For accredited investors evaluating LE reports during pre-investment diligence, the practical reading framework covers eight standard sections: insured demographic profile, medical records summary, impairment scoring detail, mortality multiplier, central LE estimate with confidence intervals, methodology disclosure, underwriter credentials, and firm A/E ratio track record. Industry data and methodology guidance is published by the Life Insurance Settlement Association (LISA). The A/E (actual-to-expected) ratio remains the single most useful quality metric for evaluating underwriter reliability across portfolios — sustained values in the 95-105% range across meaningful sample sizes indicate calibrated methodology; sustained deviations above or below that range warrant investigation.
Invest in life settlements with institutional-quality underwriting diligence
HYV applies the full diligence framework on every opportunity — independent LE underwriting from recognized firms, dual reports on high-value policies, complete methodology disclosure, A/E track record verification.
Frequently asked questions
What is life settlement underwriting and why does it matter?
Life settlement underwriting is the process by which independent specialist firms estimate the life expectancy of an insured policyholder. The estimate anchors every other calculation in the investment thesis — purchase price, projected IRR, premium reserve sizing, and holding period assumption. A ±12-24 month error in life expectancy can move IRR projections by 200-400 basis points in either direction. This makes underwriting quality the single most consequential diligence variable in a life settlement investment. The institutional standard requires independent underwriting from recognized firms operating under Actuarial Standards Board ASOP No. 48.
Which underwriting firms produce institutional-quality LE reports?
Four firms produce roughly 90% of institutional LE underwriting in the U.S. life settlement market: 21st Services (founded 1997, broad senior-life specialty), ISC Services (founded 2003, strong oncology and cardiovascular methodology), Fasano Associates (founded 1999 by industry pioneer Michael Fasano, proprietary mortality table), and Predictive Resources (founded 2010, technology-forward algorithm-driven approach). All four operate under ASOP No. 48 with documented methodology, peer review, and A/E ratio tracking. Reports from less-recognized firms or platform in-house underwriting represent a different quality tier and warrant additional investor skepticism.
What is the debit/credit system in life expectancy underwriting?
The debit/credit system is the operational core of life settlement underwriting methodology. Underwriters review the insured's medical conditions and apply "debits" (which increase mortality risk above baseline) or "credits" (which decrease mortality risk below baseline). Common scoring includes diabetes at 50-100 debits, controlled hypertension at 25-50 debits, coronary artery disease with stents at 100-200 debits, and active malignancy at 200-400+ debits. Final scoring is expressed as a mortality multiplier — a percentage of standard population mortality (e.g., 150% means 1.5× standard mortality risk). The multiplier is applied against a base mortality table to produce the modified mortality curve specific to the insured.
What is the A/E ratio and why is it important?
The A/E (actual-to-expected) ratio compares actual mortality observed in an underwriter's case portfolio to the expected mortality the underwriter projected at the time of underwriting. An A/E of 100% means the firm is calibrated correctly — actuals match expectations. Above 100% means actuals are coming in heavier (insureds dying sooner than projected, IRR outperforming for investors). Below 100% means actuals are coming in lighter (insureds living longer, IRR compressing for investors). Sustained values in the 95-105% range across meaningful sample sizes indicate calibrated methodology; sustained deviation outside that range warrants investigation. A/E is the single best metric for evaluating underwriter reliability over time.
What does ASOP No. 48 mean for life settlement underwriting?
ASOP No. 48 — Actuarial Standard of Practice 48 — is the framework published by the Actuarial Standards Board governing professional standards for life settlement mortality analysis. It establishes requirements around methodology disclosure, peer review, qualifications of underwriting personnel, and documentation completeness. Reports that don't reference ASOP 48 compliance are operating below the institutional benchmark. For accredited investors evaluating LE reports during diligence, ASOP 48 disclosure should appear in the methodology section and represent a baseline quality marker — not a differentiator, but a minimum threshold below which reports shouldn't be accepted.
Should an investor require dual LE reports on every policy?
Not on every policy, but typically on policies above $1M-$2M face value. Dual reports from two of the four major firms provide cross-validation that single-source underwriting cannot — the additional cost (typically $1,500-$3,000 per second report) is small relative to the diligence value on policies with substantial capital at stake. Below the $1M threshold, single-source reports from a recognized firm with strong A/E track record are acceptable institutional practice. Above $2M, dual reports become near-universal in institutional acquisitions. Cases with unusual impairment profiles or high uncertainty in the central estimate warrant dual reports regardless of face value.
What documentation does HYV provide about underwriting on each opportunity?
Every opportunity presented to High Yield Vault investors includes the complete LE report from a recognized independent underwriter — 21st Services, ISC, Fasano, or Predictive Resources — along with the methodology disclosure, named underwriter credentials, and supporting medical evidence summary. High-value opportunities ($1M+ face value) typically include dual independent reports for cross-validation. Investors and their advisors can review the full underwriting documentation before committing capital. Across 21 years and 438 accredited investors, this transparency standard is what anchors HYV's long-term advisor and investor relationships — diligence rigor that matches the institutional model used by Apollo, Berkshire Hathaway, and Partner Re for their direct-ownership acquisitions.
